Skip to main content

Table 2 Comparison between Candida positive and negative groups

From: Candidiasis and other oral mucosal lesions during and after interferon therapy for HCV-related chronic liver diseases

  

Total

Goup 1

Group 2

P value

Subjects (n)

 

14

7

7

 

Sex (M/F)

 

3/11

2/5

1/6

NS

Age (mean ± SD)

 

56.00 ± 12.94

61.30 ± 6.47

50.71 ± 16.00

NS

HCV genotype

1b

11 (78.57%)

6 (85.71%)

5 (71.43%)

NS

 

2a

2 (14.29%)

1 (14.29%)

1 (14.29%)

NS

 

ND (serotype 2)

1 (7.14%)

0 (0%)

1 (14.29%)

NS

HCV RNA level

High

12 (85.71%)

6 (85.71%)

6 (85.71%)

NS

 

Low

2 (14.29%)

1 (14.29%)

1 (14.29%)

NS

Weight loss during IFN therapy

 

5.69 ± 4.57

8.71 ± 2.81

2.66 ± 4.00

0.0088

Neutrophil count (μ/L)

Before IFN

2546.11 ± 793.47

2481.34 ± 599.67

2610.89 ± 997.36

NS

 

2 weeks after IFN

1229.11 ± 590.25

1260.51 ± 473.58

1197.70 ± 726.82

NS

 

3 months after IFN

1343.05 ± 584.48

1636.51 ± 670.69

1049.59 ± 298.98

NS

 

6 months after IFN

1319.11 ± 301.15

1442.69 ± 194.15

1195.53 ± 350.95

NS

 

End of treatment

1360.21 ± 547.74

1420.54 ± 401.41

1299.87 ± 693.13

NS

 

6 months after treatment

2349.21 ± 695.36

2578.63 ± 716.47

2119.80 ± 641.48

NS

PLT (x10-4/μL)

Before IFN

17.58 ± 7.06

17.54 ± 3.32

17.61 ± 9.84

NS

 

2 weeks after IFN

14.04 ± 7.28

14.37 ±4.70

13.71 ± 9.61

NS

 

3 months after IFN

13.69 ± 6.08

14.27 ± 5.36

13.11 ± 7.12

NS

 

6 months after IFN

13.20 ± 5.31

14.21 ± 4.72

12.19 ± 6.03

NS

 

End of treatment

14.45 ± 5.05

14.50 ± 4.59

14.40 ± 5.84

NS

 

6 months after treatment

16.86 ± 6.03

18.14 ± 4.29

15.59 ± 7.52

NS

Hb (g/dL)

Before IFN

13.97 ±1.08

13.91 ±1.26

14.03 ± 0.97

NS

 

2 weeks after IFN

13.04 ±1.06

13.33± 1.34

12.76 ± 0.67

NS

 

3 months after IFN

10.94 ±1.55

10.40 ±1.57

11.47 ±1.45

NS

 

6 months after IFN

10.61 ±1.73

9.81 ± 1.45

11.41 ± 1.70

NS

 

End of treatment

10.99 ±1.74

10.23 ± 1.89

11.74 ± 1.27

NS

 

6 months after treatment

13.29 ±1.48

12.99 ± 2.05

13.59 ± 0.58

NS

Alb (g/dL)

Before IFN

4.18 ± 0.35

4.10 ± 0.34

4.26 ± 0.36

NS

 

2 weeks after IFN

3.76 ± 0.48

3.75 ± 0.38

3.76 ± 0.59

NS

 

3 months after IFN

3.84 ± 0.37

3.76 ± 0.45

3.92 ± 0.28

NS

 

6 months after IFN

3.88 ± 0.33

3.74 ± 0.42

4.02 ± 0.12

0.0550

 

End of treatment

3.90 ± 0.38

3.77 ± 0.35

4.03 ± 0.39

NS

 

6 months after treatment

4.27 ± 0.35

4.23 ± 0.34

4.30 ± 0.39

NS

Salivary flow (g/2 min)

Before IFN

6.10 ± 1.81

5.86 ± 1.90

6.38 ± 1.81

NS

 

2 weeks after IFN

5.71 ± 2.60

5.88 ± 2.33

5.55 ± 3.03

NS

 

3 months after IFN

5.23 ± 2.14

4.92 ± 2.34

5.53 ± 2.06

NS

 

6 months after IFN

5.42 ± 1.97

5.32 ± 2.14

5.51 ± 1.94

NS

 

End of treatment

5.31 ± 2.06

5.33 ± 1.58

5.30 ± 2.58

NS

 

6 months end of IFN

6.02 ± 1.81

6.03 ± 1.38

6.00 ± 2.28

NS

Diabetes mellitus

positive, n (%)

2 (14.29%)

1 (14.29%)

1 (14.29%)

NS

Oral mucosal lesions

positive, n (%)

7 (50.00%)

6 (85.71%)

1 (14.29%)

0.0075

Steroid for external use

positive, n (%)

6 (42.86%)

5 (71.43%)

1 (14.29%)

0.0308

Tooth-brushing after every meal

yes, n (%)

8 (57.14%)

3 (42.86%)

5 (71.43%)

NS

Denture wearer

yes, n (%)

0 (0%)

0 (0%)

0 (0%)

NS

Administration of antifungal agent

yes, n (%)

2 (14.29%)

2 (28.57%)

0 (0%)

NS

Effect of IFN therapy

SVR , n (%)

11 (78.57%)

6 (85.71%)

5 (71.43%)

NS

  1. HCV, hepatitis C virus; IFN, interferon; M, male; F, female; ND, not detected; NS, not significant; PLT, platelets; Hb, hemoglobin; Alb, albumin.